Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
November 2025
in “
Mendeley Data
”
TLDR Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
The study evaluated the efficacy and tolerability of unorthodox dosing regimens of tofacitinib and baricitinib in pediatric patients aged 2–17 with moderate-to-severe alopecia areata over 24 weeks. Both drugs showed comparable efficacy with no significant differences in primary endpoints and were well-tolerated, with no serious adverse events. However, the unorthodox BID regimen for baricitinib was less effective in severe cases compared to the standard 4 mg QD regimen, suggesting that guideline-recommended dosing is preferable. Unorthodox dosing may be considered in special cases with therapeutic drug monitoring. Short-term use of both drugs is safe, with mild, manageable adverse events.